Bakker, Els D.
van der Pas, Stéphanie L.
Zwan, Marissa D.
Gillissen, Freek
Bouwman, Femke H.
Scheltens, Philip
van der Flier, Wiesje M.
van Maurik, Ingrid S.
Article History
Received: 17 October 2022
Accepted: 5 April 2023
First Online: 15 April 2023
Declarations
:
: The study was approved by the local Medical Ethical Committee. All patients provided written informed consent for their clinical data to be used for research purposes. Consent was obtained according to the Declaration of Helsinki.
: Not applicable.
: Research programs of WMF have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman Stichting, Biogen MA Inc, Boehringer Ingelheim, Life- MI, AVID, Roche BV, Fujifilm, Combinostics. WMF is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WMF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape). All funding is paid to her institution. WMF participated in an advisory board of Biogen MA Inc. WMF is associate editor at Brain. PS has received consultancy fees (paid to the university) from AC Immune, Alzheon, Brainstorm Cell, ImmunoBrain Checkpoint. Within his university affiliation he is PI of studies with AC Immune, FUJI-film/Toyama, NOVO-Nordisk, UCB, and Vivoryon. He is also an employee of EQT Life Sciences (formerly LSP). FHB received Optina diagnostics payments and roche, biogen payments to her institution. ISM received a consultancy fee (paid to the university) from Roche. The other authors report no financial disclosures or conflicts of interest. The sponsors had no involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the manuscript for publication.